Farnesoid X Receptor (FXR) Pipeline Report: In-depth Analysis into the Clinical Trials, Emerging Drugs, and Growth Prospects | Key Players – Gilead, Ascletis, Novartis, Enanta Pharma, and Terns Pharma

January 13 15:30 2022
Farnesoid X Receptor (FXR) Pipeline Report: In-depth Analysis into the Clinical Trials, Emerging Drugs, and Growth Prospects | Key Players - Gilead, Ascletis, Novartis, Enanta Pharma, and Terns Pharma
Delveinsight Business Research LLP
“Farnesoid X Receptor (FXR) Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Farnesoid X Receptor (FXR) Market.

The Farnesoid X Receptor (FXR) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Farnesoid X Receptor (FXR) Pipeline Analysis

Farnesoid X Receptor (FXR) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Farnesoid X Receptor (FXR) with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Farnesoid X Receptor (FXR) Treatment.

  • Farnesoid X Receptor (FXR) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Farnesoid X Receptor (FXR) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Farnesoid X Receptor (FXR) market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Farnesoid X Receptor (FXR) Therapeutics Landscape

Farnesoid X receptors (FXRs), also known as bile acid receptors (BAR) are nuclear hormone receptors expressed in high amounts in body tissues that participate in bilirubin metabolism like the liver, intestines, and kidneys. The natural ligands of the FXRs are Bile acids (BAs). FXR, as an essential liver-protective transcription factor, mainly affects liver health directly and exhibits anti-steatotic, anti-fibrotic, and anti-inflammatory activity.

The central role of FXR in various aspects of metabolism and inflammation makes FXR an attractive drug target for several diseases, such as obesity, metabolic syndrome, non-alcoholic steatohepatitis, cholestasis, and chronic inflammatory diseases of the liver and intestine. Clinical studies using FXR agonists as therapeutic tools in patients suffering from nonalcoholic fatty and cholestatic liver diseases are going on. FXR agonists are an attractive class of drugs for patients with chronic liver diseases.

Farnesoid X Receptor (FXR) Agonist Therapies covered in the report include:

  • EDP-305

  • ASC-42

  • Cilofexor

And many more

Download Sample Pages @ Farnesoid X Receptor (FXR) Therapeutics Assessment

Some of the key companies in the Farnesoid X Receptor (FXR) Agonist Market include:

  • Gilead Sciences

  • Ascletis

  • Novartis

  • Enanta Pharmaceuticals

  • Terns Pharmaceuticals

And many others

Request for Sample Pages @ Farnesoid X Receptor (FXR) Emerging Therapies and Key Companies

Table of Content

1. Report Introduction

2. Farnesoid X Receptor (FXR) 

3. Farnesoid X Receptor (FXR) Current Treatment Patterns

4. Farnesoid X Receptor (FXR) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Farnesoid X Receptor (FXR) Late Stage Products (Phase-III)

7. Farnesoid X Receptor (FXR) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Farnesoid X Receptor (FXR) Discontinued Products

13. Farnesoid X Receptor (FXR) Product Profiles

14. Farnesoid X Receptor (FXR) Key Companies

15. Farnesoid X Receptor (FXR) Key Products

16. Dormant and Discontinued Products

17. Farnesoid X Receptor (FXR) Unmet Needs

18. Farnesoid X Receptor (FXR) Future Perspectives

19. Farnesoid X Receptor (FXR) Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Visit to get the sample report: https://www.delveinsight.com/sample-request/farnesoid-x-receptor-fxr-agonist-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market